C-RAD Presentation at ESTRO Meeting

Press release 2013-04-10


C-RAD presented its complete product portfolio on the ESTRO Meeting in Vienna. Around 40 customers attended the clinical presentation of CATALYST HD.

The annual ESTRO meeting is the largest event in Europe where companies working in radiation therapy meet with clinicians and partners. The C-RAD booth was centrally in the exhibition hall. For the first time the Cyrpa booth has been integrated in the C-RAD stand.

 

On the main stage in the booth the CATALYST HD™ system has been presented. It was the first time that the system has been shown on a European exhibition. Presentations with a model allowed a realistic demonstration of the applications for Patient Positioning, Motion Monitoring and Respiratory Gating. The GEMini™ was demonstrated in combination with the software package from Cablon Medical for portal dosimetry and imaging. Also the joint product of C-RAD and Cyrpa for 4D Imaging and Virtual Simulation has been demonstrated to clinical customers as well as representatives from the major CT vendors.

 

During the exhibition C-RAD organized site visits of a clinical CATALYST HD™ installation in Vienna. Around 40 customers joined the presentation of the system. Varian organized visits to the same radiation therapy center to present their equipment.

 

Tim Thurn, CEO, C-RAD AB:

“Compared to the already successful presentation last year we counted almost 50% more customer contacts. Specifically the high interest in CATALYST HD™ and GEMini™ made me confident that C-RAD is continuing its way into a successful future.”

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail investors@c-rad.com

 

The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528).

 

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 28 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian  and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD’s Certified Adviser.


Attachments

PR 20140410 ESTRO 2014 docx.pdf